Creating sustainable value
Astorg strongly believes responsible investment can lower risk and increase financial returns for our funds and for our portfolio companies while also benefiting society as a whole. This is why Environmental, Social and Governance aspects are key to Astorg’s activities and are fully integrated into our policies and processes.
ESG Governance team
Our ESG programme is based on our firm belief that sustainable business brings higher returns and is key if we want to meet future sustainability challenges successfully. Viviana OcchionorelliESG Director
Initiatives we’re involved in
Strategy and 2022 Objectives
1. Integrating ESG principles into the investment process
100% of due diligence before offer validation integrates ESG aspects
2. Ensuring portfolio companies have an ESG programme
100% of Astorg portfolio companies adopted an ESG programme which includes:
- An ESG representative
- An ESG strategy
- An ESG action plan with KPIs approved and discussed at Board level
- An internal ESG committee
3. Ensuring portfolio companies improve their ESG processes and reduce their social and environmental footprint
100% of Astorg portfolio companies to carry out at least:
- 1 initiative to reduce their environmental footprint
- 1 initiative to improve the protection and well-being of their employees
- 1 initiative to improve their data security and protection process
- 1 initiative to improve their governance process
Companies disclosing their carbon footprint (scope 1, 2 and 3)
Companies with an Ecovadis Sustainability Rating
ESG and the investment process
We incorporate ESG criteria at every stage of our investment process.
Before investment, we conduct ESG screening and analysis of the targeted investments in order to identify any material breach against Astorg’s prohibited or restricted investments. Once the opportunity of a new investment is validated, we undertake specific ESG due diligences focusing on the investment’s material aspects in order to assess potential related risks and to identify possible opportunities.
During the ownership phase, we monitor ESG progress within our portfolio by engaging with the companies’ management and supporting their ESG programmes, placing realistic expectations on the companies through an action plan reviewed at board level on a yearly basis.
When exiting an investment, we seek to show evidence of the contribution of the company’s progress on ESG to its performance and we work closely with the company’s management to prepare it to answer to ESG-related questions from prospective buyers.
Our ESG programme
Astorg’s ESG approach has a very strong focus on strengthening our portfolio companies’ ESG performance and in supporting internal sustainability initiatives. For this, we have set up an entire programme to ensure continual improvement of our portfolio’s ESG performance.
We organise three ESG events per year gathering all our portfolio companies’ ESG representatives around specific topics such as climate change and supply chain sustainability. Our ESG events aim to enable sharing of experiences and best practices, as well as provide training and encouragement for ESG initiatives within our companies.
We have set up a network of sustainability leaders within our portfolio companies with the aim to share best practices and lead ESG programmes internally.
We run a yearly data collection campaign to measure and report our portfolio’s ESG performance on a number of environmental, social and governance indicators.
As part of our commitment to the Initiative Climat 2020, we measure our portfolio’s carbon footprint and we set up climate action plans in order to reduce our companies’ carbon footprint and to unlock innovative opportunities to adapt to climate change.
We integrate responsible investment principles into our investment process, our portfolio companies and our own corporate culture.
Audiotonix is the global market leader in the design, engineering and manufacture of professional audio mixing consoles.
Investment year: 2017TMTIn Portfolio
HRA is an innovative OTC pharma company with leading positions in Europe and in the US.
Investment year: 2016HealthcareIn Portfolio